These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24373770)

  • 1. Structural basis of prion inhibition by phenothiazine compounds.
    Baral PK; Swayampakula M; Rout MK; Kav NN; Spyracopoulos L; Aguzzi A; James MN
    Structure; 2014 Feb; 22(2):291-303. PubMed ID: 24373770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of recombinant prions with compounds of therapeutical significance.
    Georgieva D; Schwark D; von Bergen M; Redecke L; Genov N; Betzel C
    Biochem Biophys Res Commun; 2006 Jun; 344(2):463-70. PubMed ID: 16630566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Dynamics Simulation Study on the Binding and Stabilization Mechanism of Antiprion Compounds to the "Hot Spot" Region of PrP
    Zhou S; Liu X; An X; Yao X; Liu H
    ACS Chem Neurosci; 2017 Nov; 8(11):2446-2456. PubMed ID: 28795797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody.
    Abskharon RN; Giachin G; Wohlkonig A; Soror SH; Pardon E; Legname G; Steyaert J
    J Am Chem Soc; 2014 Jan; 136(3):937-44. PubMed ID: 24400836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects.
    Christen B; Hornemann S; Damberger FF; Wüthrich K
    J Mol Biol; 2009 Jun; 389(5):833-45. PubMed ID: 19393664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Horse prion protein NMR structure and comparisons with related variants of the mouse prion protein.
    Pérez DR; Damberger FF; Wüthrich K
    J Mol Biol; 2010 Jul; 400(2):121-8. PubMed ID: 20460128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the molecular basis of inherited prion diseases: NMR structure of the human prion protein with V210I mutation.
    Biljan I; Ilc G; Giachin G; Raspadori A; Zhukov I; Plavec J; Legname G
    J Mol Biol; 2011 Sep; 412(4):660-73. PubMed ID: 21839748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Korth C; May BC; Cohen FE; Prusiner SB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9836-41. PubMed ID: 11504948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding.
    Choi J; Govindaraj RG; Hyeon JW; Lee K; Ma S; Kim SY; Lee J; No KT
    Chem Biol Drug Des; 2017 Jun; 89(6):907-917. PubMed ID: 27933736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics studies on the NMR and X-ray structures of rabbit prion proteins.
    Zhang J; Zhang Y
    J Theor Biol; 2014 Feb; 342():70-82. PubMed ID: 24184221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics studies on 3D structures of the hydrophobic region PrP(109-136).
    Zhang J; Zhang Y
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):509-19. PubMed ID: 23563221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversibility of prion misfolding: insights from constant-pH molecular dynamics simulations.
    Vila-Viçosa D; Campos SR; Baptista AM; Machuqueiro M
    J Phys Chem B; 2012 Aug; 116(30):8812-21. PubMed ID: 22803931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prion protein oligomer and its neurotoxicity.
    Huang P; Lian F; Wen Y; Guo C; Lin D
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disassociation of β1-α1-β2 from the α2-α3 domain of prion protein (PrP) is a prerequisite for the conformational conversion of PrP
    Chandrasekaran P; Santosh Kumar C; Rangachari K; Sekar K
    Int J Biol Macromol; 2019 Sep; 136():368-376. PubMed ID: 31207327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into alternate aggregated prion protein forms.
    Polano M; Bek A; Benetti F; Lazzarino M; Legname G
    J Mol Biol; 2009 Nov; 393(5):1033-42. PubMed ID: 19720066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
    Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
    J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amino-terminal PrP domain is crucial to modulate prion misfolding and aggregation.
    Cordeiro Y; Kraineva J; Gomes MP; Lopes MH; Martins VR; Lima LM; Foguel D; Winter R; Silva JL
    Biophys J; 2005 Oct; 89(4):2667-76. PubMed ID: 16040743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed computational analysis revealed mutation V210I on PrP induced conformational conversion on β2-α2 loop and α2-α3.
    Chandrasekaran P; Rajasekaran R
    Mol Biosyst; 2016 Oct; 12(10):3223-33. PubMed ID: 27523988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.